Ross G Vickery
Overview
Explore the profile of Ross G Vickery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long D, Armstrong S, Beattie D, Campbell C, Church T, Colson P, et al.
ACS Med Chem Lett
. 2019 Dec;
10(12):1641-1647.
PMID: 31857840
The effects of opioids in the central nervous system (CNS) provide significant benefit in the treatment of pain but can also lead to physical dependence and addiction, which has contributed...
2.
Jiang L, Beattie D, Jacobsen J, Kintz S, Obedencio G, Saito D, et al.
Bioorg Med Chem Lett
. 2017 May;
27(13):2926-2930.
PMID: 28499731
Gastrointestinal dysfunction as a consequence of the use of opioid analgesics is of significant clinical concern. First generation drugs to treat these opioid-induced side-effects were limited by their negative impact...
3.
McKinnell R, Armstrong S, Beattie D, Fatheree P, Long D, Marquess D, et al.
Bioorg Med Chem Lett
. 2013 Jun;
23(14):4210-5.
PMID: 23756062
The discovery of a series of 5-HT4 receptor agonists based on a novel 2-alkylbenzimidazole aromatic core is described. Optimization of the 2-substituent of the benzimidazole ring led to a series...
4.
Tsuruda P, Vickery R, Long D, Armstrong S, Beattie D
Naunyn Schmiedebergs Arch Pharmacol
. 2013 Apr;
386(6):479-91.
PMID: 23549670
The clinical efficacy of opioid receptor antagonists for the treatment of opioid-induced constipation (OIC) is established. Peripherally selective antagonists are intended to provide OIC symptom relief without compromising the analgesic...
5.
Armstrong S, Campbell C, Richardson C, Vickery R, Tsuruda P, Long D, et al.
Naunyn Schmiedebergs Arch Pharmacol
. 2013 Mar;
386(6):471-8.
PMID: 23512167
The in vivo preclinical pharmacodynamic profile of TD-1211, a selective opioid receptor antagonist currently under development for the treatment of opioid-induced constipation, was compared to that of the clinically studied...
6.
Long D, Armstrong S, Beattie D, Choi S, Fatheree P, Gendron R, et al.
Bioorg Med Chem Lett
. 2012 Sep;
22(19):6048-52.
PMID: 22959244
Utilization of Theravance's multivalent approach to drug discovery towards 5-HT(4) receptor agonists with a focus on identification of neutral (non-charged at physiological pH) secondary binding groups is described. Optimization of...
7.
Long D, Armstrong S, Beattie D, Choi S, Fatheree P, Gendron R, et al.
Bioorg Med Chem Lett
. 2012 Jun;
22(14):4849-53.
PMID: 22683222
Further application of our multivalent approach to drug discovery directed to 5-HT(4) receptor agonists is described. Optimization of the linker and secondary binding amine in the indazole-tropane primary binding group...
8.
Beattie D, Armstrong S, Vickery R, Tsuruda P, Campbell C, Richardson C, et al.
Front Pharmacol
. 2011 Jun;
2:25.
PMID: 21687517
This study evaluated the in vitro and in vivo pharmacological properties of TD-8954, a potent and selective 5-HT(4) receptor agonist. TD-8954 had high affinity (pK(i) = 9.4) for human recombinant...
9.
McKinnell R, Armstrong S, Beattie D, Choi S, Fatheree P, Gendron R, et al.
J Med Chem
. 2009 Aug;
52(17):5330-43.
PMID: 19663444
5-HT(4) receptor agonists such as tegaserod have demonstrated efficacy in the treatment of constipation predominant irritable bowel syndrome (IBS-C), a highly prevalent disorder characterized by chronic constipation and impairment of...